Historical Manual Updates

Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date	Manual Section	Add/Remove/Modify	Description
11/29/2021	Appendix D: How to Distinguish Infusion Types	Modify	Updated to include gene therapy information
4/23/2024	4100: Cellular Therapy Essential Data Follow-Up	Modify	Updated blue box above question 24: The disease relapse or progression questions are applicate applicable for malignant diseases that do not generate when a disease specific form s (e.g., AML, CML, MDS, MPN) are not present or and for the following products are reported in question 1: Letetresgene autoleucel, Other product, or No product name.
10/27/2021	4100: Cellular Therapy Essential Data Follow-Up	Modify	Added the commercially available product names ‘Breyanzi’ and ‘Abecma’ to the red warning box below question 148: This question will enable only if the commercially available product ‘Kymriah’, ‘Breyanzi’, or ‘Abecma’ is selected in question 1 and can only be completed on the 100 day and 6 month follow-up forms.
9/15/2021	Cellular Therapy Manuals	Add	Added statement for REMS reporting: REMS reporting: infusions can be reported without research consent if the center is utilizing CIBMTR to support their REMS reporting needs in meeting the requirements for the commercially available CAR-T products.
5/12/2021	4100: Cellular Therapy Essential Data Follow-Up	Add	Added new example 4 for hypogammaglobulinemia resolution date when testing is not exactly at 3 months.
3/17/2021	4000: Cellular Therapy Essential Data Pre-Infusion	Modify	Clarification added to the blue note box about reporting co-morbidities within 6 months of the cellular therapy: Please report co-morbidities that occurred were detected within six months of the cellular therapy, which is different than HCT reporting. The 6 month rule applies to assessments that need to be performed in order to determine if a comorbidity is present (i.e., PFT for pulmonary, liver values for hepatic, creatinine for renal, BMI for obesity, etc.). If the co-morbidity is denoted as “ANY history”, the 6 month rule does not apply.
1/7/2021	4100: Cellular Therapy Essential Data Follow-Up	Add	Clarified when to report hypogammaglobulinemia, how to report date of onset and date of resolution. Several examples have been added.

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.